As of close of business last night, Relay Therapeutics Inc’s stock clocked out at $6.83, down -2.84% from its previous closing price of $7.03. On the day, 715040 shares were traded.
Ratios:
To gain a deeper understanding of RLAY’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 25.44 and its Current Ratio is at 25.44. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.06.
On April 19, 2023, Raymond James Upgraded its rating to Strong Buy which previously was Outperform but kept the price unchanged to $29.
On April 13, 2023, Raymond James started tracking the stock assigning a Outperform rating and target price of $29.Raymond James initiated its Outperform rating on April 13, 2023, with a $29 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 27 ’24 when Bergstrom Donald A sold 765 shares for $7.70 per share. The transaction valued at 5,890 led to the insider holds 530,113 shares of the business.
Catinazzo Thomas sold 348 shares of RLAY for $2,680 on Mar 27 ’24. The Chief Financial Officer now owns 341,498 shares after completing the transaction at $7.70 per share. On Mar 27 ’24, another insider, Adams Brian, who serves as the Chief Legal Officer of the company, sold 348 shares for $7.70 each. As a result, the insider received 2,680 and left with 327,390 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 35.07 while its Price-to-Book (P/B) ratio in mrq is 1.16.
Stock Price History:
Over the past 52 weeks, RLAY has reached a high of $18.67, while it has fallen to a 52-week low of $5.95.
Shares Statistics:
A total of 127.46M shares are outstanding, with a floating share count of 92.21M. Insiders hold about 29.71% of the company’s shares, while institutions hold 71.69% stake in the company.
Earnings Estimates
As of right now, Dave & Buster’s Entertainment, analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is $12.46, with high estimates of $9.57 and low estimates of $6.83.
Analysts are recommending an EPS of between $Technology and $Healthcare for the fiscal current year, implying an average EPS of $Financial Services.
